8-K: INVO Bioscience Faces Funding Shortfall as NAYA Bioscience Fails to Meet Second Tranche Payment

INVO Bioscience is seeking alternative funding after NAYA Bioscience failed to deliver a $500,000 payment for preferred stock by the agreed deadline.

Summary

• INVO Bioscience entered into a securities purchase agreement with NAYA Bioscience on December 29, 2023, for the sale of 1,000,000 shares of Series A Preferred Stock at $5.00 per share.
• The agreement stipulated that NAYA's purchases would be made in tranches according to a Minimum Interim Pipe Schedule.
• NAYA failed to fund the second tranche of $500,000, which was due no later than January 19, 2024.
• Due to this shortfall, INVO Bioscience is now actively seeking alternative funding sources.
• This funding issue is related to a previously announced merger agreement between INVO Bioscience and NAYA.

Sentiment

Score: 3

Explanation: The document reveals a significant funding shortfall due to a failed payment, which is a negative development for the company. The need to seek alternative funding adds uncertainty.

Negatives

• NAYA Bioscience failed to meet its payment obligation of $500,000 for the second tranche of preferred stock.
• INVO Bioscience is now facing a funding shortfall and must seek alternative financing.

Risks

• The failure of NAYA to meet its funding obligation creates uncertainty about the merger agreement.
• INVO Bioscience may face challenges in securing alternative funding on favorable terms.
• The company's financial stability could be impacted by the funding shortfall.

Future Outlook

INVO Bioscience is actively seeking alternative funding to address the shortfall caused by NAYA's failure to meet its payment obligation.

Management Comments

• Steven Shum, Chief Executive Officer of INVO Bioscience, signed the report on behalf of the company.

Industry Context

This situation highlights the risks associated with financing agreements in the biotech sector, where funding can be volatile and subject to delays or cancellations.

Comparison to Industry Standards

• It is not uncommon for biotech companies to rely on staged funding rounds, but the failure of a partner to meet payment obligations is a significant setback.
• Other companies such as Aytu BioScience and Acer Therapeutics have faced similar funding challenges, highlighting the importance of robust due diligence and contingency planning.
• The failure of NAYA to meet its obligations is a negative signal, as it suggests a lack of financial stability or commitment from the partner.

Stakeholder Impact

• Shareholders may be concerned about the funding shortfall and its potential impact on the company's financial stability.
• Employees may experience uncertainty due to the financial challenges.
• Customers and suppliers may be indirectly affected by the company's financial situation.

Next Steps

• INVO Bioscience will seek alternative funding to cover the $500,000 shortfall.
• The company will likely need to reassess its merger agreement with NAYA Bioscience.

Key Dates

Keywords

INVO Bioscience, NAYA Bioscience, Funding Shortfall, Preferred Stock, Merger Agreement, Securities Purchase Agreement, Alternative Funding